Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Gutteridge, W. E.
1989.
Parasite vaccines versus anti-parasite drugs: rivals or running mates?.
Parasitology,
Vol. 98,
Issue. S1,
p.
S87.
Bjorvatn, Bjarne
and
Helland, Dag E.
1990.
Vaccinations in Health Strategies of Developing Countries: The Role of Biotechnology and Social Sciences.
Scandinavian Journal of Infectious Diseases,
Vol. 22,
Issue. sup76,
p.
1.
Handman, E
1990.
Study of Leishmania major-infected macrophages by use of lipophosphoglycan-specific monoclonal antibodies.
Infection and Immunity,
Vol. 58,
Issue. 7,
p.
2297.
Nascimento, E
Mayrink, W
da Costa, C A
Michalick, M S
Melo, M N
Barros, G C
Dias, M
Antunes, C M
Lima, M S
and
Taboada, D C
1990.
Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses.
Infection and Immunity,
Vol. 58,
Issue. 7,
p.
2198.
Gutteridge, Win E.
1991.
Control of parasitic diseases: a complementary role for vaccines and drugs.
Immunology Letters,
Vol. 30,
Issue. 2,
p.
261.
Moss, Jeffrey T.
and
Wilson, James P.
1992.
Current Treatment Recommendations for Leishmaniasis.
Annals of Pharmacotherapy,
Vol. 26,
Issue. 11,
p.
1452.
Belazzoug, S.
1992.
Leishmaniasis in Mediterranean countries.
Veterinary Parasitology,
Vol. 44,
Issue. 1-2,
p.
15.
Soto Mancipe, Jaime
1992.
Experiencias con vacunas contra la leishmaniasis.
Revista de las Fuerzas Armadas,
p.
109.
Brabin, Loretta
and
Brabin, Bernard J.
1992.
Advances in Parasitology Volume 31.
Vol. 31,
Issue. ,
p.
1.
Handman, Emanuela
1992.
Molecular Immunology.
Vol. 5,
Issue. ,
p.
133.
Olobo, Joseph O.
and
Reid, Graham D.F.
1993.
Delayed-type hypersensitivity responses in vervet monkeys self-cured from experimental cutaneous leishmaniasis.
Acta Tropica,
Vol. 52,
Issue. 4,
p.
309.
Castés, Marianella
Blackwell, Jenefer
Trujillo, Dinorah
Formica, Santina
Cabrera, Maira
Zorrilla, Gelù
Rodas, Arcady
Castellanos, Pedro Luìs
and
Convit, Jacinto
1994.
Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-γ production.
Vaccine,
Vol. 12,
Issue. 11,
p.
1041.
Koff, Amy Beth
and
Rosen, Theodore
1994.
Treatment of cutaneous leishmaniasis.
Journal of the American Academy of Dermatology,
Vol. 31,
Issue. 5,
p.
693.
Melby, P C
Andrade-Narvaez, F J
Darnell, B J
Valencia-Pacheco, G
Tryon, V V
and
Palomo-Cetina, A
1994.
Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis.
Infection and Immunity,
Vol. 62,
Issue. 3,
p.
837.
Aebischer, T.
1994.
Recurrent cutaneous leishmaniasis: A role for persistent parasites?.
Parasitology Today,
Vol. 10,
Issue. 1,
p.
25.
Dubois, P.
and
Pereira da Silva, L.
1995.
Towards a vaccine against asexual blood stage infection by Plasmodium falciparum.
Research in Immunology,
Vol. 146,
Issue. 4-5,
p.
263.
Schnur, Lionel F.
and
Greenblatt, Charles L.
1995.
Parasitic Protozoa.
p.
1.
Hommel, M.
Jaffe, C. L.
Travi, B.
and
Milon, G.
1995.
Experimental models for leishmaniasis and for testing anti-leishmanial vaccines.
Annals of Tropical Medicine & Parasitology,
Vol. 89,
Issue. sup1,
p.
55.
Magill, Alan J.
1995.
Epidemiology of the Leishmaniases.
Dermatologic Clinics,
Vol. 13,
Issue. 3,
p.
505.
Sousa, Claris B. Palatnik de
Gomes, Elza M.
Souza, Edilma Paraguai de
Santos, Wania R. dos
Macedo, Sirley R. de
Medeiros, Linnete V. de
and
Luz, Kleber
1996.
The FML (Fucose Mannose Ligand) of Leishmania donovani: a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar.
Revista da Sociedade Brasileira de Medicina Tropical,
Vol. 29,
Issue. 2,
p.
153.